{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T02:10:02Z","timestamp":1780107002271,"version":"3.54.0"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To explore the efficacy and safety of Iguratimod intervention in Primary Sjogren\u2019s syndrome (pSS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Many databases were searched to collect the RCTs. Three independent reviewers extracted data and assessed the quality of the studies based on the Cochrane Handbook. The statistical analysis was done by RevMan 5.3 and STATA. The quality of evidence was evaluated by GRADE tool.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty-nine RCTs with 2258 participants were included in this review. The meta-analysis shows that: iguratimod experiment group can reduce the ESSPRI score (WMD -1.93 [-2.33, -1.52], P&amp;lt;0.00001), ESSDAI score (WMD -1.39 [-1.81, -0.98], P&amp;lt;0.00001), Schirmer\u2019s test (WMD 1.77 [0.85, 2.70], P=0.0002), RF (WMD -5.78 [-7.59, -3.97], P&amp;lt;0.00001), and decrease the ESR level (WMD -7.05 [-9.84, -4.26], P&amp;lt;0.00001). Meanwhile, the summary result showed the addiction of Iguratimod may not increase the adverse events. The adverse events were mainly gastrointestinal discomfort, abnormal liver function, and rash and itching. The quality of evidence of adverse events was moderate. Referring to minimal clinically important difference (MCID), the improvement of ESSPRI is clinically significant, and the improvement of ESSDAI for patients older than 60 years old may be clinically significant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Based on current evidence, iguratimod can effectively reduce ESSPRI score, ESSDAI score, Schirmer\u2019s test score and decrease systemic inflammatory response (such as ESR level and RF level) without increasing the probability of adverse events. The recommended course of treatment is at least 12 weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?<\/jats:uri>, identifier CRD42020220770.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.924730","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T10:22:33Z","timestamp":1659003753000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["A Systematic Review and Meta-Analysis of 19 Randomized Controlled Trials of Iguratimod Combined With Other Therapies for Sjogren\u2019s Syndrome"],"prefix":"10.3389","volume":"13","author":[{"given":"Liuting","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wensa","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganpeng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.clim.2017.04.005","article-title":"Sjogren's Syndrome: Clinical Aspects","volume":"182","author":"Vivino","year":"2017","journal-title":"Clin Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.12968\/hmed.2017.78.8.438","article-title":"Sj\u00f6gren's Syndrome","volume":"78","author":"Thorne","year":"2017","journal-title":"Br J Hosp Med (Lond)."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66990-5","article-title":"Sj\u00f6gren's Syndrome...","volume":"366","author":"Fox","year":"2005","journal-title":"Lancet"},{"key":"B4","first-page":"3","article-title":"One Year in Review 2019: Sj\u00f6gren's Syndrome","author":"Cafaro","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/eos.12536","article-title":"Current Concepts on Sj\u00f6gren's Syndrome - Classification Criteria and Biomarkers","volume":"126","author":"Jonsson","year":"2018","journal-title":"Eur J Oral Sci"},{"key":"B6","doi-asserted-by":"publisher","first-page":"691","DOI":"10.4140\/TCP.n.2018.691.","article-title":"Management of Primary Sj\u00f6gren's Syndrome","volume":"33","author":"Marshall","year":"2018","journal-title":"Consult Pharm"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4153-8","article-title":"Advances in the Diagnosis and Treatment of Sjogren's Syndrome","volume":"37","author":"Chen","year":"2018","journal-title":"Clin Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1080\/14397595.2018.1546268","article-title":"Targeting Primary Sj\u00f6gren's Syndrome","volume":"9","author":"Odani","year":"2019","journal-title":"Mod Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.7326\/m13-1085","article-title":"Treatment of Primary Sj\u00f6gren Syndrome With Rituximab: A Randomized Trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann Intern Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212268","article-title":"Effect of Rituximab on a Salivary Gland Ultrasound Score in Primary Sj\u00f6gren's Syndrome: Results of the TRACTISS Randomised Double-Blind Multicentre Substudy","volume":"77","author":"Fisher","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218599","article-title":"Efficacy and Safety of Abatacept in Active Primary Sj\u00f6gren's Syndrome: Results of a Phase III, Randomised, Placebo-Controlled Trial","volume":"80","author":"Baer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2021.1951224","article-title":"An Update of Targeted Therapeutic Options for Primary Sj\u00f6gren Syndrome: Current Status and Future Development","author":"Retamozo","year":"2021","journal-title":"Expert Opin Pharmacother."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-012-0724-8","article-title":"Concomitant Iguratimod Therapy in Patients With Active Rheumatoid Arthritis Despite Stable Doses of Methotrexate: A Randomized, Double-Blind, Placebo-Controlled Trial","volume":"23","author":"Ishiguro","year":"2013","journal-title":"Mod Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/00029330-200804010-00008","article-title":"Safety and Efficacy of T-614 in the Treatment of Patients With Active Rheumatoid Arthritis: A Double Blind, Randomized, Placebo-Controlled and Multicenter Trial","volume":"121","author":"L\u00fc","year":"2008","journal-title":"Chin Med J (Engl)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/art.24643","article-title":"Multicenter, Randomized, Double-Blind, Controlled Trial of Treatment of Active Rheumatoid Arthritis With T-614 Compared With Methotrexate","volume":"61","author":"Lu","year":"2009","journal-title":"Arthritis Rheum"},{"key":"B16","doi-asserted-by":"publisher","first-page":"356040","DOI":"10.1155\/2015\/356040","article-title":"Regulatory Effect of Iguratimod on the Balance of Th Subsets and Inhibition of Inflammatory Cytokines in Patients With Rheumatoid Arthritis","volume":"2015","author":"Xu","year":"2015","journal-title":"Mediators Inflammation"},{"key":"B17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/rheumatology\/keg381","article-title":"Inhibitory Effects of an Anti-Rheumatic Agent T-614 on Immunoglobulin Production by Cultured B Cells and Rheumatoid Synovial Tissues Engrafted Into SCID Mice","volume":"42","author":"Tanaka","year":"2003","journal-title":"Rheumatol Oxford (Oxford)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/PL00000291","article-title":"An Anti-Rheumatic Agent T-614 Inhibits NF-kappaB Activation in LPS- and TNF-Alpha-Stimulated THP-1 Cells Without Interfering With IkappaBalphadegradation","volume":"51","author":"Aikawa","year":"2002","journal-title":"Inflamm Res"},{"key":"B19","first-page":"310+2","article-title":"Study on the Regulatory Effects of IGU on CD3+T Cells and Cytokines Il-6 in Patients With Rheumatoid Arthritis","volume":"30","author":"Wang","year":"2015","journal-title":"Chin J Ctrl Endem Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.16462\/j.cnki.zhjbkz.2018.01.017","article-title":"Clinical Study of Effectiveness and Safety of Iguratimod in Treating Primary Sjogren\u2019s Syndrome","volume":"22","author":"Wang","year":"2018","journal-title":"Chin J Dis Control Prev"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.621208","article-title":"Effectiveness and Safety of Iguratimod in Treating Primary Sj\u00f6gren's Syndrome: A Systematic Review and Meta-Analysis","volume":"12","author":"Pu","year":"2021","journal-title":"Front Pharmacol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1136\/annrheumdis-2021-222054","article-title":"NECESSITY WP5 - STAR Development Working Group; NECESSITY WP5- STAR Development Working Group. Development and Preliminary Validation of the Sj\u00f6gren's Tool for Assessing Response (STAR): A Consensual Composite Score for Assessing Treatment Effect in Primary Sj\u00f6gren's Syndrome","volume":"81","author":"Seror","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B23","article-title":"Chapter 8: Assessing Risk of Bias in Included Studies","volume-title":"Cochrane Handbook or Systematic Reviews of Interventions Version 5.1.0","author":"Deeks","year":"2020"},{"key":"B24","article-title":"Chapter 9: Analyzing Data and Undertaking Meta-Analyses","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Deeks","year":"2020"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.13507\/j.issn.1674-3474.2019.12.024","article-title":"Clinical Analysis of 46 Cases of Primary Sjogren\u2019s Syndrome Treated by Ilamud","volume":"33","author":"Luo","year":"2019","journal-title":"Chin J Pract Diagnosis Ther"},{"key":"B26","first-page":"147+149","article-title":"Observation of the Changes of ESR, CRP, IgG, IgA, IgM Levels in Patients With Primary Sjogren\u2019s Syndrome by Iramod","volume":"5","author":"Miao","year":"2018","journal-title":"Electronic J Clin Med Literature"},{"key":"B27","first-page":"150","article-title":"Clinical Analysis of Iramod in the Treatment of Primary Sjogren\u2019s Syndrome","volume":"18","author":"Yu","year":"2020","journal-title":"Guide to Chin Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3969\/j.issn.1672-0369.2020.18.001","article-title":"Clinical Effect of Methylprednisolone Combined With Ilamod in the Treatment of Elderly Patients With Primary Sjogren\u2019s Syndrome","volume":"32","author":"Gu","year":"2020","journal-title":"Chin Natl Health Med"},{"key":"B29","article-title":"Observation on the Effect of Methylprednisolone Combined With Iramud in the Treatment of Primary Sjogren\u2019s Syndrome","volume":"31","author":"Zhao","year":"2019","journal-title":"Chin Natl Health Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.15912\/j.cnki.gocm.2019.32.081","article-title":"Comparative Observation of Iguratimod and Hydroxychloroquine in the Treatment of Patients With Sj\u00f6gren's Syndrome","volume":"17","author":"Zhang","year":"2019","journal-title":"Chin Med Guide"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.11655\/zgywylc2020.21.040","article-title":"Comparison of the Efficacy and Safety of Iguratimod and Hydroxychloroquine in the Treatment of Sj\u00f6gren's Syndrome","volume":"20","author":"Zhao","year":"2020","journal-title":"Chin Med Clin Med"},{"key":"B32","article-title":"Analysis of the Effect of Iguratimod Combined With Hydroxychloroquine in the Treatment of Sj\u00f6gren's Syndrome","volume":"36","author":"Jia","year":"2020","journal-title":"Gansu Sci Technol"},{"key":"B33","article-title":"To Explore the Effect of Iguratimod in the Treatment of Primary Sj\u00f6gren's Syndrome","volume":"31","author":"Zhuang","year":"2020","journal-title":"Special Health"},{"key":"B34","article-title":"Efficacy and Safety of Iguratimod and Hydroxychloroquine in the Treatment of Sj\u00f6gren's Syndrome","volume":"11","author":"Wei","year":"2019","journal-title":"Drugs and Clinical Practice"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1009-4393.2022.08.057","article-title":"Clinical Effect of Methylprednisolone Combined With Iguratimod in the Treatment of Primary Sj\u00f6gren's Syndrome and its Influence on the Level of Immunoglobulin","volume":"28","author":"Gu","year":"2022","journal-title":"Contemp Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/03009742.2020.1809701","article-title":"Efficacy and Safety of Iguratimod on Patients With Primary Sj\u00f6gren's Syndrome: A Randomized, Placebo-Controlled Clinical Trial","volume":"29","author":"Shao","year":"2020","journal-title":"Scand J Rheumatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1008-8296.2019.02.020","article-title":"Observation on the Efficacy and Safety of Iramod in the Treatment of Primary Sjogren\u2019s Syndrome in the Elderly","volume":"25","author":"Wang","year":"2019","journal-title":"Geriatrics Health Care"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.3969\/j.issn.1672-3511.2020.09.022","article-title":"Hydroxychloroquine Sulfate Combined With Total Glucosides of Paeony and Ilamod in the Treatment of Primary Sjogren\u2019s Syndrome","volume":"32","author":"Xie","year":"2020","journal-title":"Western Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.19381\/j.issn.1001-7585.2022.02.025","article-title":"Analysis of Curative Effect of Iguratimod in the Treatment of Elderly Patients With pSS and its Effect on B Cell Activity and Secretion Level of Immunoglobulin G","volume":"35","author":"Chen","year":"2022","journal-title":"Med Theory Pract"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-020-01490-6","article-title":"The Efficacy and Mechanism for Action of Iguratimod in Primary Sj\u00f6gren's Syndrome Patients","volume":"40","author":"Jiang","year":"2020","journal-title":"Int Ophthalmol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1002-3429.2016.08.029","article-title":"Observation on the Clinical Effect of Iramod Combined Treatment of Primary Sjogren\u2019s Syndrome","volume":"29","author":"Jiang","year":"2016","journal-title":"Clin Misdiagnosis Mistreatment"},{"key":"B42","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3969\/j.issn.1672-3511.2014.06.015","article-title":"Observation on the Curative Effect of Iramod in the Treatment of Primary Sjogren\u2019s Syndrome","volume":"26","author":"Jiang","year":"2014","journal-title":"Western Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1002-3429.2016.08.029","article-title":"Observation on the Clinical Effect of Iramod in the Treatment of Primary Sjogren\u2019s Syndrome","volume":"48","author":"Bai","year":"2019","journal-title":"Shanxi Med J"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1002-3429.2016.08.029","article-title":"Efficacy of Methylprednisolone Combined With Ilamod in the Treatment of Primary Sjogren\u2019s Syndrome and its Effect on Immunoglobulin Levels","volume":"27","author":"Li","year":"2018","journal-title":"China Pharm"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.11966\/j.issn.2095-994X.2020.06.05.63","article-title":"Efficacy of Methylprednisolone Combined With Ilamod in the Treatment of Primary Sjogren\u2019s Syndrome and its Effect on Immunoglobulin Levels","volume":"6","author":"Li","year":"2020","journal-title":"World Complex Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3969\/j.issn.1004-7484.2017.34.395","article-title":"Analysis of Clinical Effect of Iguratimod Combined Treatment on Primary Sj\u00f6gren's Syndrome","volume":"27","author":"Xia","year":"2017","journal-title":"China Health Nutr"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1671-6450.2017.09.013","article-title":"Comparison of the Efficacy and Safety of Iguratimod and Hydroxychloroquine in the Treatment of Patients With Sj\u00f6gren's Syndrome","volume":"16","author":"Xu","year":"2017","journal-title":"J Difficult Difficult Dis"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1674-7860.2018.24.041","article-title":"Efficacy and Safety of Iguratimod and Hydroxychloroquine in the Treatment of Patients With Sj\u00f6gren's Syndrome","volume":"10","author":"Luo","year":"2018","journal-title":"Clin Res Traditional Chin Med"},{"key":"B49","article-title":"Efficacy and Mechanism of Iguratimod in the Treatment of Sj\u00f6gren's Syndrome","volume":"48","author":"Zhang","year":"2019","journal-title":"Shaanxi Med J"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14164\/j.cnki.cn11-5581\/r.2019.20.001","article-title":"Efficacy Evaluation of Iguratimod in the Treatment of Sj\u00f6gren's Syndrome Complicated With Interstitial Pulmonary Disease","volume":"13","author":"Zhang","year":"2019","journal-title":"China Modern Med Appl"},{"key":"B51","article-title":"Effects of Iguratimod on the Levels of ESR, CRP and Immunoglobulin in Patients With Primary Sj\u00f6gren's Syndrome","volume":"42","author":"Liang","year":"2021","journal-title":"Shanghai Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.16050\/j.cnki.issn1674-6309.2022.02.008","article-title":"Efficacy of Iguratimod in the Treatment of Sj\u00f6gren's Syndrome Patients and its Influence on Immune Function","volume":"44","author":"Rao","year":"2022","journal-title":"J Ningxia Med Univ"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.15887\/j.cnki.13-1389\/r.2021.31.018","article-title":"Clinical Efficacy of Iguratimod Combined With Hydroxychloroquine Sulfate in the Treatment of Primary Sj\u00f6gren's Syndrome","volume":"14","author":"Lu","year":"2021","journal-title":"J Clin Rational Med"},{"key":"B54","unstructured":"Clinical Observation of Shure Cunjin Granules Combined With Iguratimod in the Treatment of Primary Sj\u00f6gren's Syndrome With High IgG[D]\n            JiangH\n          10.27138\/d.cnki.ghuzc.2021.000018Hunan University of Traditional Chin Med2021"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109704","article-title":"Molecular Mechanisms and Clinical Application of Iguratimod: A Review","volume":"122","author":"Jiang","year":"2020","journal-title":"BioMed Pharmacother."},{"key":"B56","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1080\/14397595.2020.1789335","article-title":"Iguratimod Treatment Reduces Disease Activity in Early Primary Sj\u00f6gren's Syndrome: An Open-Label Pilot Study","volume":"31","author":"Chen","year":"2021","journal-title":"Mod Rheumatol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-04986-9","article-title":"Relative Efficacy and Safety of Iguratimod Monotherapy for the Treatment of Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis","volume":"39","author":"Shrestha","year":"2020","journal-title":"Clin Rheumatol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/310628","article-title":"Efficacy and Safety of Iguratimod for the Treatment of Rheumatoid Arthritis","volume":"2013","author":"Li","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2018.1510879","article-title":"The Three-Year Efficacy of Iguratimod in Clinical Daily Practice in Patients With Rheumatoid Arthritis","volume":"29","author":"Suto","year":"2019","journal-title":"Mod Rheumatol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3668-8","article-title":"Effects of Iguratimod on the Levels of Circulating Regulators of Bone Remodeling and Bone Remodeling Markers in Patients With Rheumatoid Arthritis","volume":"36","author":"Wang","year":"2017","journal-title":"Clin Rheumatol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-006-0543-x","article-title":"Long-Term Safety Study of Iguratimod in Patients With Rheumatoid Arthritis","volume":"17","author":"Hara","year":"2007","journal-title":"Mod Rheumatol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2018.1460230","article-title":"Safety and Effectiveness of Iguratimod in Patients With Rheumatoid Arthritis: Final Report of a 52-Week, Multicenter Postmarketing Surveillance Study","volume":"29","author":"Mimori","year":"2019","journal-title":"Mod Rheumatol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2018.1481565","article-title":"Iguratimod, a Synthetic Disease Modifying Anti-Rheumatic Drug Inhibiting the Activation of NF-\u03bab and Production of RANKL: Its Efficacy, Radiographic Changes, Safety and Predictors Over Two Years' Treatment for Japanese Rheumatoid Arthritis Patients","volume":"29","author":"Ishikawa","year":"2019","journal-title":"Mod Rheumatol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2014.998361","article-title":"Efficacy at 52 Weeks of Daily Clinical Use of Iguratimodin Patients With Rheumatoid Arthritis","volume":"25","author":"Okamura","year":"2015","journal-title":"Mod Rheumatol"},{"key":"B65","volume-title":"GRADEpro Guideline Development Tool [Software]","year":"2015"},{"key":"B66","volume-title":"GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations","author":"Sch\u00fcnemann","year":"2013"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.924730\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T10:23:12Z","timestamp":1659003792000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.924730\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,28]]},"references-count":66,"alternative-id":["10.3389\/fimmu.2022.924730"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.924730","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,28]]},"article-number":"924730"}}